Facebook beats Q4 2015 expectations with 1.59B monthly active users and $5.84B in revenue

Facebook's iconic sign on display outside its Menlo Park, Calif. headquarters.

Facebook has beaten expectations in its Q4 FY2015 earnings. The company announced that it now had 1.59 billion monthly active users now on its social network. For the quarter, it generated $5.8 billion in revenue. It didn’t immediately attribute its successful quarter to anything although mobile and a growing community likely did the trick.

In terms of its financials, Wall Street analysts expected an average of $0.68 earnings per share and revenue of $5.37 billion. Its user numbers also trumped expectations as some predicted that there would be 1.58 billion monthly active users this quarter.

The number of both daily and monthly average users continues to increase, indicating that people are not growing tired of the company’s various services and that there’s still more opportunities for advertisers to take advantage of. With respect to daily average users, it now stands at 1.04 billion, an increase of 17 percent. Mobile continues to be the preferred way of using Facebook as it now counts 1.44 billion monthly active users.

Facebook’s Q4 revenue grew 52 percent from same time period a year ago, moving from $3.85 billion to $5.84 billion. Much of it was from the advertising efforts that the company has, which had an annual increase of 57 percent and brought in nearly $5.64 billion. Mobile advertising continues to play a big part in Facebook’s success as it generated 80 percent of the company’s ad revenue, an increase of 69 percent from the previous year.

Much of the interest in Facebook has been around not just its core app, where people are looking at the average revenue per user (ARPU), but also the growth and ad strength of Instagram. The company didn’t disclose any information about Instagram in its initial reports, but may say something in the follow-up earnings call later today.

Shares in the company were down 2.97 percent for the day, closing at $94.45. It’s currently up 5.61 percent in after-hours trading.

More to follow. Please refresh for updates.

More information:

Powered by VBProfiles

Newron Pharmaceuticals to Present at the 18th Annual BIO CEO & Investor Conference in New York


MILAN–(BUSINESS WIRE)–January 27, 2016–

Newron Pharmaceuticals S.p.A. (“Newron”) [Ticker: SIX: NWRN], a research and development company focused on novel central nervous system (CNS) and pain therapies, today announced that Stefan Weber, CEO, will present at the 18th Annual BIO CEO & Investor Conference in New York, NY on Feb. 9, 2016 at 9:00 a.m. ET in the Conrad Room at the Waldorf Astoria New York.

The BIO CEO & Investor Conference is the largest investor conference focused on established and emerging publicly traded and select private biotech companies. Each year, the BIO CEO & Investor Conference provides a neutral forum where institutional investors, industry analysts and senior biotechnology executives have the opportunity to shape the future investment landscape of the biotechnology industry. The conference features issue-oriented plenary sessions and educational sessions focused on hot therapeutic areas and key business issues, company presentations, one-on-one meetings and networking opportunities.

About Newron Pharmaceuticals
Newron (SIX: NWRN) is a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central nervous system (CNS) and pain. The Company is headquartered in Bresso near Milan, Italy. Marketing authorization in the EU for Xadago® (safinamide) for the treatment of Parkinson’s disease was granted by the EU Commission in February 2015, followed by Swissmedic’s grant of the marketing authorization for Switzerland in November 2015. The drug has been launched by Newron’s partner Zambon in the first key EU country – Germany – in May 2015, and Switzerland in January 2016. The New Drug Application (NDA) has been accepted for review by the FDA, as reported in March 2015. Zambon has the rights to develop and commercialize safinamide globally, excluding Japan and other key Asian territories, where Meiji Seika has the rights to develop and commercialize the compound. Newron’s additional projects are based on highly promising treatments for rare disease patients and are at various stages of clinical development. They include sarizotan for patients with Rett syndrome, for which Newron received Orphan Drug Designation in both the US and the EU, ralfinamide for patients with specific rare pain indications, and NW-3509 as potentially the first add-on therapy for the treatment of patients with positive symptoms of schizophrenia. For additional information, please visit http://www.newron.com.

Important Notices
This document contains forward-looking statements, including (without limitation) about (1) Newron’s ability to develop and expand its business, successfully complete development of its current product candidates and current and future collaborations for the development and commercialisation of its product candidates and reduce costs (including staff costs), (2) the market for drugs to treat CNS diseases and pain conditions, (3) Newron’s anticipated future revenues, capital expenditures and financial resources, and (4) assumptions underlying any such statements. In some cases these statements and assumptions can be identified by the fact that they use words such as “will”, “anticipate”, “estimate”, “expect”, “project”, “intend”, “plan”, “believe”, “target”, and other words and terms of similar meaning. All statements, other than historical facts, contained herein regarding Newron’s strategy, goals, plans, future financial position, projected revenues and costs and prospects are forward-looking statements.
By their very nature, such statements and assumptions involve inherent risks and uncertainties, both general and specific, and risks exist that predictions, forecasts, projections and other outcomes described, assumed or implied therein will not be achieved. Future events and actual results could differ materially from those set out in, contemplated by or underlying the forward-looking statements due to a number of important factors. These factors include (without limitation) (1) uncertainties in the discovery, development or marketing of products, including without limitation negative results of clinical trials or research projects or unexpected side effects, (2) delay or inability in obtaining regulatory approvals or bringing products to market, (3) future market acceptance of products, (4) loss of or inability to obtain adequate protection for intellectual property rights, (5) inability to raise additional funds, (6) success of existing and entry into future collaborations and licensing agreements, (7) litigation, (8) loss of key executive or other employees, (9) adverse publicity and news coverage, and (10) competition, regulatory, legislative and judicial developments or changes in market and/or overall economic conditions.
Newron may not actually achieve the plans, intentions or expectations disclosed in forward-looking statements and assumptions underlying any such statements may prove wrong. Investors should therefore not place undue reliance on them. There can be no assurance that actual results of Newron’s research programmes, development activities, commercialisation plans, collaborations and operations will not differ materially from the expectations set out in such forward-looking statements or underlying assumptions.
Newron does not undertake any obligation to publicly up-date or revise forward looking statements except as may be required by applicable regulations of the SIX Swiss Exchange where the shares of Newron are listed.
This document does not contain or constitute an offer or invitation to purchase or subscribe for any securities of Newron and no part of it shall form the basis of or be relied upon in connection with any contract or commitment whatsoever.

Newron Pharmaceuticals
Stefan Weber, +39 02 6103 46 26
E-mail: [email protected]
FTI Consulting
Julia Phillips, +44 (0)20 3727 1000
IRF Communications
Martin Meier-Pfister, +41 43 244 81 40
MC Services AG
Anne Hennecke, +49 211 52925222
[email protected]
David Connolly, +1-617-374-8800, Ext. 108
[email protected]
Investors and analysts
Newron Pharmaceuticals
Stefan Weber, +39 02 6103 46 30
[email protected]
MC Services AG
Anne Hennecke, +49 211 52925222
[email protected]
Kristina Coppola, +1-617-374-8800, Ext. 105
[email protected]

Medium now lets publishers schedule posts, link Twitter accounts to publications

Medium's new logo

Medium has announced that it has begun rolling out several new features aimed at publishers. Over the course of this week, the company will introduce a way to schedule posts for publication, an integration with Twitter designed to increase readership, and statistics around its Letter offering.

The new features being introduced are geared specifically to publishers and writers and Medium hopes that it will enhance the overall experience they have when using the platform to share their thoughts and ideas.


With the schedule to publish feature, writers can specify a date and time in the future for when a story should be published. It’s very similar to other content management tools like WordPress and writers will enjoy it, especially when they have embargoes or articles they think will ideally resonate better when published at a different day or time.

While Medium has already supported an integration with Twitter, the company has implemented a new way of using it when it comes to publications. Popular publications have a strong following on the social network as users treat it as akin to being an RSS feed. So what Medium has done is take users of a particular Twitter account and if they have a Medium account, they’ll automatically become a follower of the publication.


Publishers can’t use their publication’s Twitter account to log into Medium.

In June 2015, Medium introduced a new offering called Letters. It was designed to be a delivery method for blog posts to help writers better connect with their readers in the form of an email newsletter. Publications likely find this feature valuable, but need to know more about its impact. And this is why the company has begun rolling out stats for Letters to a wider audience — it came online in January 2016. You’ll now receive statistics for each mailing just like you would in an email marketing campaign. It displays the number of mailings sent, how many readers opened it, and clicked on a link.


As the company begins to bring on board more content partners such as The Synapse, Those People, The Awl, Discovery Communications, MSNBC, and more than 1,500 active publishers, it needs to make sure that the platform has the necessary tools to suit the writer’s needs. If you’re looking to spread your ideas on Medium, it would be great to have the flexibility to choose when you want, that your social media followers are part of the conversation, and you can track its impact. And that’s what the company has done today.

More information:

Powered by VBProfiles

We’re no closer to a ‘Surface Phone’ today than yesterday


The Internet, or at least the subsection that closely follows Microsoft activity, is abuzz today with news that the company has registered a domain that could point to the development of the mythical “Surface Phone.” As many publications are reporting, “Microsoft now owns surfacephone.com” (via WMPoweruser).

Except it really doesn’t mean anything, and it certainly has nothing to do with any current work by the now-combined Surface and Lumia teams on a Surface-branded handset.

According to Whoisology, a historical database of WHOIS records, Microsoft acquired the domain sometime between August and December 2014. That’s a full 14 to 17 months ago, and the same year that its acquisition of Nokia’s Devices and Services division closed. (The domain was first registered in May 2007.)

What’s more, Microsoft owns a lot of domains: at least 67,681 of them, according to the latest Whoisology database (which is updated every four months).


Of the 1,680,376 domains and subdomains Sitedossier has cataloged for the nameserver ns1.msft.net, a full 55 of them begin with the word “surface” — and the list is far from complete (it doesn’t even include surfacephone.com, for instance). They are:

surface-svcs.com, surface-svcs.net, surface-svcs.org, surface.ca, surface.com, surface.de, surface.info, surface.lt, surface.org, surface.se, surfaceacademy2009.codeplex.com, surfaceavailabilityapp.com, surfaceavailabilityapp.net, surfacebing.com, surfaceblog.net, surfacebooks.com, surfacecam.com, surfacecar.com, surfacecasino.biz, surfacecoffeetables.com, surfacedeals.com, surfacekeyboard.com, surfacelaptop.com, surfacelaptop.net, surfacelaptop.org, surfacemicrosoft.com, surfacemicrosoft.net, surfacemouse.com, surfacemovies.net, surfacemultitouch.com, surfacemultitouch.net, surfacenotebook.net, surfacepad.com, surfacepad.net, surfacepc.net, surfacepoker.net, surfaceretail.com, surfaceskype.com, surfaceslate.com, surfaceslate.net, surfacestore.net, surfacetablet.net, surfacetabletpen.com, surfacetouch.com, surfacetouch.net, surfacetypecovers.com, surfacevcr.com, surfacevcr.net, surfacevertical.com, surfacevertical.net, surfacevideo.net, surfacevirtualconcierge.com, surfacevirtualconcierge.net, surfacewebcam.com, surfacezune.com

Still, from this sampling alone, we see a number of generic surface brandings such as surfacemouse, surfacelaptop, surfacecam, and even surfacecar.

The registration of surfacephone.com over a year ago likely had little to do with any actual company plans, instead representing just a small piece of Microsoft’s overall effort to secure as many tech-related, Surface-branded domains as it could.

In fact, Surface was not originally used as a name of a consumer line of tablets, but rather a multi-touch table for enterprise rebranded as PixelSense.

Microsoft may well be developing a phone for commercial release inside its Panos Panay-led Surface division, but the recent discovery of the surfacephone.com domain — which currently redirects to the Surface landing page on Microsoft.com — is hardly evidence of it.

Massachusetts is investigating high cost of hepatitis C drug

The Massachusetts attorney general's office said Wednesday that it is investigating whether the makers of a breakthrough treatment for hepatitis C are violating state law by pricing the drugs too high. Attorney General Maura Healey on Wednesday publicly released the letter she sent Jan. 22 to John Martin, chairman and chief executive of California-based Gilead Sciences Inc. In it, she called on the company to adjust its pricing structure to make two drugs more widely accessible to those who need them.

Google Brings Commenting To Sheets And Slides On Mobile

Commenting made easier Docs Google announced today a couple of updates to the commenting features in its Google Apps productivity suite . These include the launch of mobile commenting in the iOS and Android apps for Slides and Sheets. Thanks to this, the commenting experience in Google’s apps is now (almost) the same across all of its apps — whether on the web or on mobile. I’m not sure why… Read More

Google revamps commenting in Docs, adds support to Sheets and Slides on Android and iOS


Google today updated Google Docs with improved commenting support, making it easier to insert a comment or add a teammate to the conversation. At the same time, mobile commenting has been added to both Sheets and Slides on Android and iOS. You can download the latest versions now directly from Google Play (Docs, Sheets, and Slides) and Apple’s App Store (Docs, Sheets, and Slides).

First of all, commenting is always just a click or tap away. You should now see a little floating bubble on the right hand side of the doc that lets you add a new comment.

Next, adding a teammate to the doc is as simple as typing their name in a comment. Their email address will appear, and you just have to tap or click to include them in the conversation.

Last but not least, Google has finally rounded out mobile commenting support. While Docs has had mobile commenting support since 2012, Sheets and Slides have only gained “the same rich commenting experience” on Android and iOS today.

Today happens to be National Chocolate Cake Day, so Google has taken the opportunity to promote today’s update with an incredibly forced video:

Here’s the backstory:

When Jim, one of the engineers on the Google Slides team, brought a zucchini chocolate cake into the office last week, we knew we had to get the recipe. So we asked him and his wife, Alison, to let us in on the family secret—just in time for National Chocolate Cake Day. They worked together in Slides (mobile commenting across Google Docs just launched today!) to perfect the recipe.

If you want to put zucchinis in your chocolate cake, the recipe is available on Google Slides.

EA pulls its booth out of E3 and focuses instead on fan event

EA Play

Electronic Arts has completely revamped its plans for the Electronic Entertainment Expo (E3), the big video game trade show that draws tens of thousands of people — and it won’t be on the show floor.

The move could be seen as a way to get closer to fans as well as grab more of the spotlight from other companies who compete for media and industry attention at the big trade show, which takes place the week of June 12 in Los Angeles and has traditionally been gaming’s most important event for blockbusters and the studios that make them.

E3 is the place where the whole PC and console game industry goes to reveal new games for the year, drawing more than 50,000 attendees to the Los Angeles convention center. But EA will hold an event called EA Play that will run from June 12 to June 14 at Club Nokia in Los Angeles, just outside the convention center.

The publisher will also hold a one-day event on June 12 at The Mermaid Event Center in London. Sign-ups for a newsletter for more information are available now.

EA said it will still hold a press conference that will take place on Sunday, at EA Play, instead of at its usual venue on Monday. EA will have no booth at the show, but it will have private meeting rooms and be listed as an exhibitor. That will still leave a gaping hole in the convention center, as EA had a splashy booth with giant screens and lots of stations for playing games. Now it will likely entertain even more guests at the Club Nokia venue.

E3 traditionally doesn’t admit fans, as it is an industry trade show. However, the show did allow 5,000 into the event last year.

An EA spokesman said, “It’s an all-new event that puts our players first and creates a play experience built around them.  Play LA will be at Club Nokia at LA Live on June 12-14, and Play London will be at The Mermaid on June 12.  Both events will kick off with a live press conference and offer hands-on with our games, and more.”

Rich Taylor, senior vice president of communications at the Entertainment Software Association (it puts on E3) said in a statement, “EA’s player experience underscores E3 as the global launchpad for video game news, announcements, and excitement. As always, we continue to look forward to their contributions to E3 week and can’t wait to play the games ourselves.”

We’ve also asked for more explanation from EA.